ACADIA Pharmaceuticals Inc (ACAD)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 258,075 | -51,036 | -213,444 | -167,519 | -280,973 |
| Revenue | US$ in thousands | 957,797 | 726,437 | 517,235 | 484,145 | 441,755 |
| Pretax margin | 26.94% | -7.03% | -41.27% | -34.60% | -63.60% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $258,075K ÷ $957,797K
= 26.94%
ACADIA Pharmaceuticals Inc's pretax margin has shown a significant improvement over the years, as indicated by the data provided. In December 2020, the company experienced a negative pretax margin of -63.60%, signifying that its expenses exceeded its revenues before accounting for taxes. However, by December 2024, ACADIA Pharmaceuticals Inc managed to turn around its performance remarkably, achieving a positive pretax margin of 26.94%.
The trend in pretax margin reflects the company's ability to control costs, increase operational efficiency, and enhance overall profitability. The substantial improvement in pretax margin from negative values to a positive figure indicates that ACADIA Pharmaceuticals Inc has likely implemented strategic initiatives to enhance its financial performance and drive sustainable growth.
Investors and stakeholders may view this positive shift in pretax margin favorably, as it demonstrates the company's potential for improved financial health and profitability in the future. Nonetheless, ongoing monitoring of ACADIA Pharmaceuticals Inc's financial performance will be essential to assess the sustainability of this positive trend and to identify any potential risks or challenges that may impact the company's profitability in the long term.
Peer comparison
Dec 31, 2024